Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
15
BBLG Quote, Financials, Valuation and Earnings
Last price:
$2.94
Seasonality move
:
53.88%
Day range:
$2.89 - $2.97
52-week range:
$2.86 - $25.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.55x
Volume:
44.8K
Avg. volume:
1M
1-year change:
-57.31%
Market cap:
$1.6M
Revenue:
--
EPS (TTM):
-$23.25
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bone Biologics has 670.55% upside to fair value with a price target of $22.50 per share.
BBLG vs. S&P 500
-
Over the past 5 trading days, Bone Biologics has underperformed the S&P 500 by -3.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bone Biologics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bone Biologics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Bone Biologics reported revenues of --.
Earnings Growth
-
Bone Biologics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bone Biologics reported earnings per share of -$1.92.
Enterprise value:
-1.2M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$6.1M | -$7.2M | -$4.4M | -$903.5K | -$1M | |
| EBITDA | -$6.1M | -$7.2M | -$4.4M | -$903.5K | -$1M | |
| Diluted EPS | -$422.10 | -$85.93 | -$23.25 | -$7.86 | -$1.92 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $71.2K | $6.1M | $6.8M | $3.8M | $3.2M | |
| Total Assets | $71.2K | $6.1M | $6.8M | $3.8M | $3.2M | |
| Current Liabilities | $14.2M | $54.9K | $4M | $164.6K | $251.2K | |
| Total Liabilities | $14.2M | $54.9K | $4M | $164.6K | $251.2K | |
| Total Equity | -$14.1M | $6M | $2.8M | $3.7M | $2.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.1M | -$9.5M | -$3.7M | -$1.3M | -$926.1K | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $4.4M | $6.5M | $3.3M | $1.5M | $347.6K | |
| Free Cash Flow | -$4.1M | -$9.5M | -$3.7M | -$1.3M | -$926.1K | |
BBLG
Sector
Market Cap
$1.6M
$35.2M
Price % of 52-Week High
11.45%
48.58%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-57.31%
-36.85%
Beta (5-Year)
1.215
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.96
200-day SMA
Sell
Level
$6.13
Bollinger Bands (100)
Sell
Level
3.84 - 5.3
Chaikin Money Flow
Sell
Level
-22.2M
20-day SMA
Sell
Level
$3.87
Relative Strength Index (RSI14)
Sell
Level
34.80
ADX Line
Sell
Level
17.01
Williams %R
Buy
Level
-98.1982
50-day SMA
Sell
Level
$4.42
MACD (12, 26)
Sell
Level
-0.53
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
76.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Stock Forecast FAQ
In the current month, BBLG has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BBLG average analyst price target in the past 3 months is $22.50.
-
Where Will Bone Biologics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bone Biologics share price will rise to $22.50 per share over the next 12 months.
-
What Do Analysts Say About Bone Biologics?
Analysts are divided on their view about Bone Biologics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bone Biologics is a Sell and believe this share price will drop from its current level to $22.50.
-
What Is Bone Biologics's Price Target?
The price target for Bone Biologics over the next 1-year time period is forecast to be $22.50 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BBLG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bone Biologics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BBLG?
You can purchase shares of Bone Biologics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bone Biologics shares.
-
What Is The Bone Biologics Share Price Today?
Bone Biologics was last trading at $2.94 per share. This represents the most recent stock quote for Bone Biologics. Yesterday, Bone Biologics closed at $2.92 per share.
-
How To Buy Bone Biologics Stock Online?
In order to purchase Bone Biologics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 13.2% over the past day.
